Androski Lindsay 4

What Happened

• Lindsay Androski, President & CEO and Director of Arbutus Biopharma (ABUS), received equity awards on 2026-02-02 totaling 99,700 shares: 28,000 restricted stock units (RSUs) and a 71,700-share derivative award (option). The grants were awarded at $0.00 (no cash purchase). These are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-02-02; reported same day (timely filing).
• Award amounts: 28,000 RSUs (F1) and 71,700 derivative/option shares (listed as derivative).
• Vesting: RSUs vest in three equal annual installments beginning one year from the grant date (F1). The option/derivative vests over four years at 1/48th per month starting one month after the grant (F3).
• Tax withholding: On each RSU vesting date, common shares will be automatically sold to cover tax withholding in a non-discretionary "sell-to-cover" transaction (F1).
• Price note: The grants are reported at $0.00; F2 in the filing references the Nasdaq closing price on the grant date but the numeric closing price is not provided in the excerpt.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Reported on the same date as the transactions; no late filing indicated.

Context

• RSUs are a contingent right to receive shares at vesting (common executive compensation); the option award is a derivative that vests over time and must be exercised to convert to shares. Automatic sales to cover taxes are routine and do not necessarily indicate a change in insider sentiment. These awards increase potential future insider ownership as they vest, but are standard long-term incentive compensation rather than open-market buying.